NKTR · NASDAQ
Nektar Therapeutics
$37.22 -1.45 (-3.75%)
Company overview
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Its pipeline includes Bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist in Phase 3 trials for metastatic melanoma, renal cell carcinoma, bladder cancer, head and neck cancer, and adjuvant melanoma, with additional trials in lung and urothelial cancers; NKTR-358, a cytokine Treg stimulant in Phase 2 for systemic lupus erythematosus and ulcerative colitis; NKTR-255, an IL-15 receptor agonist in Phase 1/2 for non-Hodgkin's lymphoma, multiple myeloma, and other cancers; and NKTR-262, a toll-like receptor agonist in Phase 1/2 for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.1B
- Employees
- 61
- Headquarters
- San Francisco, CA
- Website
- nektar.com
- CEO
- Howard W. Robin
- Listed
- May 3, 1994
- P/E
- -4.42
- Dividend yield
- 0.00%
Company financials
- Revenue
- $55.6M
- Gross profit
- $55.3M
- Operating income
- -$125M
- EBITDA
- -$120M
- Net income
- -$158M
- EPS
- -$8.42
- Total assets
- $763M
- Total debt
- $143M
- Gross margin
- 99.38%
- Net margin
- -284.18%
- Earnings yield
- -22.62%
Showing FY 2025
NKTR
1D
NASDAQ
O38.01H38.80L37.00C38.65+0.38 (+0.99%)Vol1.02M